Other languages Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
13.45 ^USD	-1.54%		-10.57%	-48.62%

May. 16	Tourmaline Bio, Inc Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial	CI
May. 13	Tourmaline Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tourmaline Bio, Inc Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial	May. 16
Tourmaline Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13
Wall Street Set to Open Higher After Fed Holds Interest Rates Steady; Initial Jobless Claims Lower Than Expected	Mar. 21
US Futures Trend Higher After Fed Decision to Hold Interest Rates Steady	Mar. 21
Top Premarket Decliners	Mar. 21
Tourmaline Reports Q4 Net Loss; Cash to Fund Operations Until 2027	Mar. 19
Tourmaline Bio, Inc. Plans to Commence a Phase 2 Trial Evaluating Quarterly Subcutaneous Dosing of TOUR006 in Patients with Elevated Cardiovascular Risk in the First Half of 2024	Mar. 19
Tourmaline Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19
Tourmaline Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19
Tourmaline Bio Insider Bought Shares Worth $3,250,000, According to a Recent SEC Filing	Jan. 31
Tourmaline Bio Prices $150 Million Common Stock Offering	Jan. 25
Tourmaline Bio, Inc. Appoints Clay Siegall to Serve as a Director	Dec. 14
Tourmaline Bio, Inc. Announces Resignation of Cariad Chester as Member of the Board of Directors	Nov. 30
Talaris Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Tourmaline Bio Insider Bought Shares Worth $280,584, According to a Recent SEC Filing	23-10-27
Tourmaline Bio Insider Bought Shares Worth $110,912, According to a Recent SEC Filing	23-10-26
Tourmaline Bio Completes Merger With Talaris Therapeutics	23-10-19
Tourmaline Bio, Inc. completed the acquisition of Talaris Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	23-10-18
Talaris Therapeutics Shareholders OK Merger With Tourmaline Bio	23-10-18
MORNING BRIEFING - USA/Asien	23-10-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Other languages

Filters